PTEN function: The long and the short of it

Trends in Biochemical Sciences

Volumn 39, Issue 4, 2014, Pages 183-190

  Hopkins, Benjamin D ^a   Hodakoski, Cindy ^a   Barrows, Douglas ^a   Mense, Sarah M ^a   Parsons, Ramon E ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

PI3K signaling; PTEN; PTEN Long

Indexed keywords

ALPHA MANNOSIDASE; ALPHA MANNOSIDASE 2C1; ENZYME VARIANT; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; REGULATOR PROTEIN; SHANK INTERACING PROTEIN LIKE 1; UNCLASSIFIED DRUG; CARRIER PROTEINS AND BINDING PROTEINS; CYTOSOLIC ALPHA MANNOSIDASE 2C1;

ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME STRUCTURE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION; ANIMAL; CELL CYCLE; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; GENOMIC INSTABILITY; METABOLISM; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CRYSTAL STRUCTURE; MUTATIONAL ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PTEN GENE; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL CYCLE; GENE EXPRESSION REGULATION; GENOMIC INSTABILITY; HUMANS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PTEN PHOSPHOHYDROLASE;

EID: 84897391926     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2014.02.006     Document Type: Review

References (87)

1. Li J., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
2. Steck P.A., et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23. 3 that is mutated in multiple advanced cancers. Nat. Genet. 1997, 15:356-362.
3. Gao J., et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 2013, 6:pl1.
4. Cerami E., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2:401-404.
5. Li D.M., Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res. 1997, 57:2124-2129.
6. Myers M.P., et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:13513-13518.
7. Maehama T., Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 1998, 273:13375-13378.
8. Stambolic V., et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998, 95:29-39.
9. 3-dependent and -independent roles for PTEN in the control of cell migration. Curr. Biol. 2007, 17:115-125.
10. Raftopoulou M., et al. Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. Science 2004, 303:1179-1181.
11. Dey N., et al. The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res. 2008, 68:1862-1871.
12. Tamura M., et al. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998, 280:1614-1617.
13. Song M.S., et al. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 2012, 13:283-296.
14. Cully M., et al. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat. Rev. Cancer 2006, 6:184-192.
15. Mayo L.D., Donner D.B. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem. Sci. 2002, 27:462-467.
16. Alimonti A., et al. Subtle variations in Pten dose determine cancer susceptibility. Nat. Genet. 2010, 42:454-458.
17. Shen-Li H., et al. Reduction of Pten dose leads to neoplastic development in multiple organs of Pten (shRNA) mice. Cancer Biol. Ther. 2010, 10:1194-1200.
18. Liaw D., et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 1997, 16:64-67.
19. Arch E.M., et al. Deletion of PTEN in a patient with Bannayan-Riley-Ruvalcaba syndrome suggests allelism with Cowden disease. Am. J. Med. Genet. 1997, 71:489-493.
20. Zhou X., et al. Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet 2001, 358:210-211.
21. Marsh D.J., et al. Allelic imbalance, including deletion of PTEN/MMACI, at the Cowden disease locus on 10q22-23, in hamartomas from patients with Cowden syndrome and germline PTEN mutation. Genes Chromosomes Cancer 1998, 21:61-69.
22. Zhou X.P., et al. Germline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults. Am. J. Hum. Genet. 2003, 73:1191-1198.
23. Butler M.G., et al. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J. Med. Genet. 2005, 42:318-321.
24. Hollander M.C., et al. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat. Rev. Cancer 2011, 11:289-301.
25. Trimboli A.J., et al. Pten in stromal fibroblasts suppresses mammary epithelial tumours. Nature 2009, 461:1084-1091.
26. Lee J.O., et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 1999, 99:323-334.
27. Walker S.M., et al. The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif. Biochem. J. 2004, 379:301-307.
28. Campbell R.B., et al. Allosteric activation of PTEN phosphatase by phosphatidylinositol 4,5-bisphosphate. J. Biol. Chem. 2003, 278:33617-33620.
29. Vazquez F., et al. Phosphorylation of the PTEN tail regulates protein stability and function. Mol. Cell. Biol. 2000, 20:5010-5018.
30. 2. J. Biol. Chem. 2002, 277:20336-20342.
31. Silva A., et al. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J. Clin. Invest. 2008, 118:3762-3774.
32. Okumura K., et al. PCAF modulates PTEN activity. J. Biol. Chem. 2006, 281:26562-26568.
33. Ikenoue T., et al. PTEN acetylation modulates its interaction with PDZ domain. Cancer Res. 2008, 68:6908-6912.
34. Wang X., et al. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 2007, 128:129-139.
35. Trotman L.C., et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 2007, 128:141-156.
36. Fouladkou F., et al. The ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability and localization. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:8585-8590.
37. Drinjakovic J., et al. E3 ligase Nedd4 promotes axon branching by downregulating PTEN. Neuron 2010, 65:341-357.
38. Van Themsche C., et al. X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN ubiquitination, content, and compartmentalization. J. Biol. Chem. 2009, 284:20462-20466.
39. Maddika S., et al. WWP2 is an E3 ubiquitin ligase for PTEN. Nat. Cell Biol. 2011, 13:728-733.
40. Lee J.T., et al. RFP-mediated ubiquitination of PTEN modulates its effect on AKT activation. Cell Res. 2013, 23:552-564.
41. Maccario H., et al. Ubiquitination of PTEN (phosphatase and tensin homolog) inhibits phosphatase activity and is enhanced by membrane targeting and hyperosmotic stress. J. Biol. Chem. 2010, 285:12620-12628.
42. Huang J., et al. SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane. Nat. Commun. 2012, 3:911.
43. Bassi C., et al. Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. Science 2013, 341:395-399.
44. Miller S.J., et al. Direct identification of PTEN phosphorylation sites. FEBS Lett. 2002, 528:145-153.
45. Torres J., Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J. Biol. Chem. 2001, 276:993-998.
46. Al-Khouri A.M., et al. Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. J. Biol. Chem. 2005, 280:35195-35202.
47. Koul D., et al. Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene 2002, 21:2357-2364.
48. Lu Y., et al. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J. Biol. Chem. 2003, 278:40057-40066.
49. Li Z., et al. Regulation of PTEN by Rho small GTPases. Nat. Cell Biol. 2005, 7:399-404.
50. Yim E.K., et al. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 2009, 15:304-314.
51. Maccario H., et al. PTEN is destabilized by phosphorylation on Thr366. Biochem. J. 2007, 405:439-444.
52. Odriozola L., et al. Regulation of PTEN activity by its carboxyl-terminal autoinhibitory domain. J. Biol. Chem. 2007, 282:23306-23315.
53. Tibarewal P., et al. PTEN protein phosphatase activity correlates with control of gene expression and invasion, a tumor-suppressing phenotype, but not with AKT activity. Sci. Signal. 2012, 5:ra18.
54. Zhang X.C., et al. Functional analysis of the protein phosphatase activity of PTEN. Biochem. J. 2012, 444:457-464.
55. Rahdar M., et al. A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:480-485.
56. Tolkacheva T., et al. Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 and 383. Cancer Res. 2001, 61:4985-4989.
57. Vazquez F., et al. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J. Biol. Chem. 2001, 276:48627-48630.
58. Okumura K., et al. Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:2703-2706.
59. Torres J., et al. Phosphorylation-regulated cleavage of the tumor suppressor PTEN by caspase-3: implications for the control of protein stability and PTEN-protein interactions. J. Biol. Chem. 2003, 278:30652-30660.
60. Ning K., et al. A novel leptin signalling pathway via PTEN inhibition in hypothalamic cell lines and pancreatic beta-cells. EMBO J. 2006, 25:2377-2387.
61. Moult P.R., et al. Leptin regulates AMPA receptor trafficking via PTEN inhibition. J. Neurosci. 2010, 30:4088-4101.
62. Patsoukis N., et al. PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2. Mol. Cell. Biol. 2013, 33:3091-3098.
63. Yang Z., et al. Reduced expression of PTEN and increased PTEN phosphorylation at residue Ser380 in gastric cancer tissues: a novel mechanism of PTEN inactivation. Clin. Res. Hepatol. Gastroenterol. 2013, 37:72-79.
64. Vo K., et al. Targeting notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation. Mol. Cancer 2011, 10:138.
65. Cao J., et al. MC1R is a potent regulator of PTEN after UV exposure in melanocytes. Mol. Cell 2013, 51:409-422.
66. Lima-Fernandes E., et al. Distinct functional outputs of PTEN signalling are controlled by dynamic association with beta-arrestins. EMBO J. 2011, 30:2557-2568.
67. Wu X., et al. Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:4233-4238.
68. Wu Y., et al. Interaction of the tumor suppressor PTEN/MMAC with a PDZ domain of MAGI3, a novel membrane-associated guanylate kinase. J. Biol. Chem. 2000, 275:21477-21485.
69. Kotelevets L., et al. Implication of the MAGI-1b/PTEN signalosome in stabilization of adherens junctions and suppression of invasiveness. FASEB J. 2005, 19:115-117.
70. Takahashi Y., et al. PTEN tumor suppressor associates with NHERF proteins to attenuate PDGF receptor signaling. EMBO J. 2006, 25:910-920.
71. Chagpar R.B., et al. Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:5471-5476.
72. Cheung L.W., et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 2011, 1:170-185.
73. Sumitomo M., et al. Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. Cancer Cell 2004, 5:67-78.
74. Fine B., et al. Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a. Science 2009, 325:1261-1265.
75. Hodakoski C., et al. Regulation of PTEN inhibition by the pleckstrin homology domain of P-REX2 during insulin signaling and glucose homeostasis. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:155-160.
76. Berger M.F., et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012, 485:502-506.
77. Ikeda F., et al. SHARPIN forms a linear ubiquitin ligase complex regulating NF-kappaB activity and apoptosis. Nature 2011, 471:637-641.
78. He L., et al. Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells. J. Clin. Invest. 2010, 120:2094-2108.
79. Wang L., Suzuki T. Dual functions for cytosolic alpha-mannosidase (Man2C1): its down-regulation causes mitochondria-dependent apoptosis independently of its alpha-mannosidase activity. J. Biol. Chem. 2013, 288:11887-11896.
80. Yue W., et al. Suppression of 6A8 alpha-mannosidase gene expression reduced the potentiality of growth and metastasis of human nasopharyngeal carcinoma. Int. J. Cancer 2004, 108:189-195.
81. Tian Y., et al. Inhibition of alpha-mannosidase Man2c1 gene expression suppresses growth of esophageal carcinoma cells through mitotic arrest and apoptosis. Cancer Sci. 2008, 99:2428-2434.
82. Xiang Z.G., et al. hMan2c1 transgene promotes tumor progress in mice. Transgenic Res. 2010, 19:67-75.
83. He L., et al. α-Mannosidase 2C1 attenuates PTEN function in prostate cancer cells. Nat. Commun. 2011, 2:307.
84. Song M.S., et al. Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell 2011, 144:187-199.
85. Putz U., et al. The tumor suppressor PTEN is exported in exosomes and has phosphatase activity in recipient cells. Sci. Signal. 2012, 5:ra70.
86. Hopkins B.D., et al. A secreted PTEN phosphatase that enters cells to alter signaling and survival. Science 2013, 341:399-402.
87. Malaney P., et al. The PTEN Long N-tail is intrinsically disordered: increased viability for PTEN therapy. Mol. Biosyst. 2013, 9:2877-2888.